- Vitamin D offers no benefit for cardiovascular disease (CVD) prevention, based on results of this meta-analysis of 21 randomized trials and 83,291 participants.
- Results represent the final nail for D in primary prevention, with an analysis adding in the newest findings from recent trials.
Why this matters
- Observational studies had suggested some benefit of D for CVD prevention.
- The title of the accompanying editorial, “ The Demise of Vitamin D for Cardiovascular Prevention ,” pretty much says it all.
- The editorial notes that vitamin D therapy remains indicated for patients with chronic kidney disease and hyperparathyroidism.
- For vitamin D vs placebo, risk ratios (95% CIs) were:
- Major cardiovascular events: 1.00 (0.95-1.06; 6243 patients),
- Myocardial infarction: 1.00 (0.93-1.08; 2550 patients),
- Stroke: 1.06 (0.98-1.15; 2354 patients),
- CVD mortality: 0.98 (0.90-1.07; 2202 patients), and
- All-cause mortality: 0.97 (0.93-1.02; 6502 patients).
- No differences seen based on sex, dosage, formulation, calcium administration.
- Meta-analysis of 21 randomized controlled trials (4 with explicit CVD outcomes); mean participant age, 65.8 years; 74.4% female.
- Outcomes: included major adverse cardiac events, stroke, mortality.
- Funding: None disclosed.
- Most trials did not specify CVD-related primary endpoint.
- No patient-level data.